secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001558370-24-003671
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure reports FY2023 net loss $62.7M; workforce cut 37% to extend cash runway to H2 2026
--------------------------------------------------------------------------------

- Cash, equivalents, and marketable securities $108.3M at Dec 31, 2023 (down from $159.9M); net loss $62.7M vs $74.7M prior year.
- Workforce reduction ~37%; internal GMP manufacturing paused; one-time restructuring charges ~$0.8M expected in Q2 2024.
- NC410 combo: 42.8% ORR (3 PRs in 7 evaluable ovarian patients); CRC cohort 10.5% ORR (2/19), median PFS 8.1 months.
- LNCB74 (B7-H4 ADC) IND planned by year-end 2024; cost-sharing with LegoChem Biosciences.
- Cash runway now expected into second half of 2026 following restructuring and cost reductions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837024003671/0001558370-24-003671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837024003671/nxtc-20240321x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-003671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer